Every 10-Q that GeoVax Labs, Inc. New (GOVX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVX filings page.
GeoVax Labs, Inc. reported Q2 2026 results with no revenue and a continued net loss as it advances its mpox/smallpox and oncology programs. For the three months ended June 30, 2026, net loss was $4.43 million, improving from $5.37 million a year earlier, as operating expenses declined to $4.44 million from $6.27 million driven by lower research and development spending.
For the first half of 2026, GeoVax recorded a net loss of $9.69 million versus $10.73 million in the prior-year period. Cash and cash equivalents were $3.14 million at June 30, 2026, with working capital of $1.46 million. The company raised approximately $7.25 million in the first half through common stock and warrant transactions, increasing shares outstanding to 7,369,243 from 1,732,147 at year-end 2025.
Management states existing cash is expected to fund operations only into September 2026 and discloses substantial doubt about the ability to continue as a going concern absent additional capital. Strategy has been reprioritized around the GEO-MVA mpox/smallpox vaccine and Gedeptin® oncology program, with the GEO-CM04S1 COVID-19 vaccine candidate discontinued. GeoVax also highlights new Nasdaq rules requiring a $5 million market value of listed securities, noting its common stock trades near that threshold and could face delisting risk.
GeoVax Labs reported a first-quarter 2026 net loss of $5.26 million, similar to the prior year, but with a much weaker balance sheet. Revenue from government contracts fell to zero after termination of a BARDA contract that had generated $1.64 million in Q1 2025.
Research and development spending was $3.90 million and general and administrative expenses were $1.37 million, both lower than a year earlier as certain program and investor-relations costs declined. Cash and cash equivalents dropped to $1.27 million as of March 31 2026, with working capital of $0.14 million.
The company financed operations through equity offerings, an at-the-market program, and warrant exercises raising roughly $1.72 million in the quarter, plus additional inducement-related warrant exercises in May. Management states existing cash is expected to fund operations only into June 2026 and discloses substantial doubt about GeoVax’s ability to continue as a going concern.
GeoVax Labs (GOVX) reported Q3 2025 results marked by a sharp revenue drop and continued losses. Revenue from government contracts was $0 in the quarter versus $2,789,484 a year ago after BARDA-directed work under the ATI‑RRPV contract was terminated for convenience on April 11, 2025. Operating expenses were $6,373,215 and the net loss was $6,318,914, or $0.31 per share.
For the nine months, revenue was $2,489,145, operating expenses totaled $19,686,436, and net loss was $17,046,348 ($0.97 per share). Cash and cash equivalents were $5,008,997, with working capital of $4,693,071. Management states existing cash funds operations into December 2025 and notes “substantial doubt” about the ability to continue as a going concern without additional capital. To support liquidity, the company completed equity financings in March (~$4.1 million net), July (~$5.5 million net), and September (~$2.3 million net), and sold shares via its ATM program (~$4.0 million net for the nine months). As of November 13, 2025, 29,705,360 shares were outstanding.